Qiagen (NYSE:QGEN) Stock Rating Upgraded by UBS Group

Qiagen (NYSE:QGEN) was upgraded by investment analysts at UBS Group to a “hold” rating in a report issued on Wednesday, Zacks reports.

Several other equities research analysts have also recently issued reports on QGEN. Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the stock a “hold” rating in a research report on Thursday, June 25th. Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 price target on shares of Qiagen in a report on Thursday, August 6th. Berenberg Bank set a $45.50 price objective on shares of Qiagen and gave the company a “hold” rating in a research note on Tuesday, July 14th. Weiss Ratings upgraded Qiagen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, August 17th. Finally, Morgan Stanley restated an “overweight” rating on shares of Qiagen in a report on Friday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Qiagen currently has an average rating of “Hold” and an average price target of $43.51.

Qiagen Price Performance

QGEN stock opened at $42.39 on Wednesday. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The stock’s fifty day simple moving average is $42.20 and its 200-day simple moving average is $40.18. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $8.74 billion, a price-to-earnings ratio of 21.72, a price-to-earnings-growth ratio of 4.20 and a beta of 0.63.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The firm had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. During the same period in the prior year, the firm posted $0.60 earnings per share. The business’s quarterly revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities research analysts expect that Qiagen will post 2.43 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise lifted its stake in Qiagen by 1.8% during the fourth quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock worth $747,000 after purchasing an additional 290 shares during the last quarter. Commerce Bank lifted its position in shares of Qiagen by 4.9% in the 4th quarter. Commerce Bank now owns 6,725 shares of the company’s stock worth $302,000 after buying an additional 314 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Qiagen by 20.8% in the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after buying an additional 317 shares during the period. Truist Financial Corp grew its position in shares of Qiagen by 4.1% during the 4th quarter. Truist Financial Corp now owns 8,421 shares of the company’s stock valued at $379,000 after buying an additional 331 shares during the last quarter. Finally, Private Advisor Group LLC grew its position in shares of Qiagen by 7.1% during the 3rd quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock valued at $256,000 after buying an additional 378 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.